SHANGHAI, November 29, 2011 /PRNewswire-Asia/ -- China Health Resource, Inc. (OTCBB: CHRI), through its wholly owned subsidiary Suining Yinfa DAR Industrial Co, Ltd (Yinfa), announces it active participation at "HOW TO BECOME A GLOBAL COMPANY NOW THROUGH ACQUISITION! Business and Legal Strategies for Chinese Companies Going Global" sponsored by Boss & Young, EvoTech Management Corporation and Loeb & Loeb LLP, a seminar held in Shanghai, PRC.
"Going global is in our next growth strategy for 2012," said Jiayin Wang, Chairman and CEO of CHRI, "and acquisitions will accelerate the manner in which we can grow our TCM platform quickest."
The company recently reported its financials with over $9.3 million in revenues and $1.8 million in net income, a 219% increase in revenues and a 141% increase in profits from the third quarter of 2010. The net earnings performance in the first three quarters has already exceeded the net profit for the entire year of 2010 by 61%.
"We have built a strong franchise base with GAP standard Chuan DAR and as evidenced by our financial growth and performance reflecting it. TCM is proving to be one of the new growth segments within the pharmaceutical industry not only in China but globally, and we believe TCM requires international standards such as GAP in order to develop into a matured industry to solidify the acceptance of TCM world-wide. The Chuan DAR and GAP standard for DAR and other TCM products are our core contribution to the TCM industry. It is time to expand our business globally, and we will be seeking global partners to do so," said Jiayin Wang.
TCM is considered one of the fastest growing segments of the healthcare industry within China and Asia. In developed countries, TCM is also gaining pace establishing its role as an alternative medicine practice as medical and pharmaceutical companies look for new and more cost effective products. TCM, where appropriate, is considered in applicable cases recognized to be of a lower cost, more natural solution and with significantly less side effects than chemical drug products.
About CHRI
China Health Resource, Inc. engages in the development, manufacturing, processing, marketing and sale of Dahurian Angelica Root (DAR) and is the only provider of GAP quality product in the People's Republic of China under the registered Trademark Chuan Baizhi™. DAR, which is also known as "Bai Zhi" in Mandarin Chinese, is an herb that is employed as an ingredient in medicine, cosmetics and food, as well as used in TCM for the treatment of pain, swelling and pustules. The Company's DAR-related products include the Bailing Capsule, Yisheng Capsule, Kimchee-Mate and Fragrant Bag, all of which are sold through regional distributors. The Company was founded in 2001 and is based in Suining, Sichuan Province
Certain statements in this document regarding financial matters, other than historical facts, and statements of our expectations, intentions, plans and beliefs, constitute "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, that are subject to certain events, risks and uncertainties that may be outside our control. The words "believe", "expect", "anticipate", "optimistic", "intend", "will", and similar expressions identify forward-looking statements. The company intends that such proclamations about future expectations, including future revenues and earnings, future business expansion plans, and all other forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. These and other risks and uncertainties related to our business are described in greater detail in our filings with the Commission. The foregoing information should be read in conjunction with these filings. We disclaim any intention or obligation to update or revise any forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made.